<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558087</url>
  </required_header>
  <id_info>
    <org_study_id>HCRN GU16-257</org_study_id>
    <nct_id>NCT03558087</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing</brief_title>
  <official_title>Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Galsky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin,
      plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to
      define the role of clinical complete response in predicting benefit in patients opting to
      avoid cystectomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the clinical complete response rate (cT0 or cTa) with gemcitabine, cisplatin, plus nivolumab</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical complete response rate will be defined as cT0 or cTa disease after gemcitabine, cisplatin, plus nivolumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment.</measure>
    <time_frame>24 months</time_frame>
    <description>Benefit will be defined as a pathologic complete response (&lt;pT1) in patients undergoing cystectomy and 2 year metastasis-free in patients pursuing surveillance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Assess adverse events according to the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder intact overall survival</measure>
    <time_frame>24 Months</time_frame>
    <description>Bladder-intact overall survival is defined as the time from initiation of treatment until death or cystectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Recurrence-free survival is defined as the time from initiation of treatment to death or recurrence, depending on which occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate in patients undergoing cystectomy</measure>
    <time_frame>24 Months</time_frame>
    <description>Pathologic complete response rate in patients undergoing radical cystectomy is defined as the proportion of patients with &lt;pT1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the association between a prespecified panel of genomic biomarkers and benefit from treatment in patients achieving a clinical complete response.</measure>
    <time_frame>24 months</time_frame>
    <description>Benefit will be defined as a pathologic complete response (p&lt;T1) in patients undergoing cystectomy and 2 years metastasis-free in patients pursuing surveillance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with &gt; cTa status will undergo cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).</description>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.</description>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.</description>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG Performance Status of ≤ 1 within 28 days prior to registration.

          -  Histological evidence of clinically localized muscle-invasive urothelial cancer of the
             bladder (i.e., ct2-4n0m0). candidate for cystectomy as per treating physician.

          -  Demonstrate adequate organ function per listed criteria:

          -  Absolute Neutrophil Count (ANC): ≥ 1.5 x 10^9/L

          -  Hemoglobin (Hgb): ≥ 9 g/dL

          -  Platelets: ≥ 100 x 10^9/L

          -  Calculated creatinine clearance: Creatinine ≤ 1.5 or creatinine clearance ≥ 60 mL/min

          -  Bilirubin: ≤ 1.5 × upper limit of normal (ULN) (except subjects with Gilbert Syndrome,
             who can have total bilirubin &lt; 3.0 mg/dL)

          -  Aspartate aminotransferase (AST) : ≤ 3 × ULN

          -  Alanine aminotransferase (ALT) : ≤ 3 × ULN

          -  All subjects must have adequate archival tissue submitted prior to registration (i.e.,
             at least 15 unstained slides or paraffin block).

          -  Women of childbearing potential (WOCBP) must use appropriate method(s) of
             contraception.

          -  Women of childbearing potential must have a negative serum or urine pregnancy within 7
             days prior to C1D1.

          -  Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year.

        Exclusion Criteria:

          -  Prior treatment with systemic chemotherapy for muscle-invasive urothelial cancer of
             the bladder

          -  Active infection requiring systemic therapy

          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
             mother is being treated on study).

          -  Any serious or uncontrolled medical disorder that, in the opinion of the investigator,
             may increase the risk associated with study participation or study drug
             administration, impair the ability of the subject to receive protocol therapy, or
             interfere with the interpretation of study results.

          -  Prior malignancy active within the previous 3 years except for locally curable cancers
             that have been apparently cured.

          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
             requiring hormone replacement, psoriasis not requiring systemic treatment, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll.

          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids and adrenal replacement
             doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active
             autoimmune disease.

          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or
             any other antibody or drug specifically targeting T-cell co-stimulation or immune
             checkpoint pathways.

          -  Grade ≥ 2 neuropathy (NCI CTCAE version 4).

          -  Prior radiation therapy for bladder cancer

          -  Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus
             ribonucleic acid (RNA) or hepatitis C antibody (HCV antibody) indicating acute or
             chronic infection.

          -  Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS).

          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis.

          -  Solid organ or allogeneic stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Galsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Galsky, MD</last_name>
    <phone>212-659-5599</phone>
    <email>matthew.galsky@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahran Lee</last_name>
    <phone>317-634-5842</phone>
    <phone_ext>41</phone_ext>
    <email>alee@hoosiercancer.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yale Kim</last_name>
      <phone>626-218-0710</phone>
      <phone_ext>80710</phone_ext>
      <email>yakim@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sumanta Pal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerity of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apoorva Vishwanath</last_name>
      <phone>323-865-0591</phone>
      <email>Apoorva.Vishwanath@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Siamak Daneshmand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Galsky, M.D.</last_name>
      <phone>212-241-8214</phone>
      <email>matthew.galsky@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Rother</last_name>
      <phone>503-494-8236</phone>
      <email>rother@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Cetnar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn Medicine Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Foster</last_name>
      <phone>215-615-2220</phone>
      <email>Sheryl.Foster@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Ronac Mamtani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie White</last_name>
      <phone>801-213-6106</phone>
      <email>Jamie.White@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Maughan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Boruch</last_name>
      <phone>608-262-4689</phone>
      <email>aboruch@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Christos Kyriakopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Matthew Galsky</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>muscle-invasive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

